acute myeloid leukemia

[Nature Communications] Researchers performed a meta-analysis of three genome-wide association studies, with replication in a fourth study, and incorporated a total of 4018 acute myeloid leukemia (AML) cases and 10488 controls, and identified a genome-wide significant risk locus for AML at 11q13.2.

[Scientific Reports] Investigators used peripheral blood and bone marrow samples from patients with acute myeloid leukemia (AML) to analyze the impact of CD157-directed antibodies in AML survival and in response to cytarabine ex vivo.

[Leukemia] Investigators demonstrated that the frequent germline pathogenic DDX41 variants characterized a clinically distinct acute myeloid leukemia (AML) entity. Features characteristic of DDX41-mutated AML included male predominance, indolent course and frequent somatic DDX41 variants.

[Critical Reviews in Oncology Hematology] Investigators review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.

[ALX Oncology Holdings, Inc.] ALX Oncology Holdings, Inc. announced the first patient has been dosed in the Phase I/II ASPEN-05 study evaluating the combination of evorpacept with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia.

[Nature Communications] The authors showed that miR-126 enhanced MYC activity through the SPRED1/PLK2-ERK-MYC axis. Genetic deletion of miR-126 significantly reduced acute myeloid leukemia rate and extended survival in CBFB-MYH11 knock-in mice.